Novo Nordisk Faces Critical Juncture Amid Legal and Competitive Pressures

The year 2025 is shaping up to be a formidable challenge for Novo Nordisk, with its share price having plummeted by more than half and its once-dominant market position showing signs of erosion. Recent developments, including a pivotal court ruling in India and new strategic plans for its next-generation drug candidate CagriSema, are introducing fresh volatility. Investors are now questioning whether these moves can finally establish a floor for the beleaguered stock or if generic competition is poised to deliver another significant blow.

The latest news arrives against a backdrop of extreme weakness for Novo Nordisk’s equity. The stock remains locked in a powerful downtrend, having lost over 52% of its value Read more...